Nang Kuang Pharmaceutical Co., Ltd.(TW:1752)
NT$29.900.00 (0.00%)
TW:1752
Nang Kuang Pharmaceutical Co., Ltd. financials statements
NT$29.90
At close:0.00 (0.00%)
Nang Kuang Pharmaceutical Co., Ltd. (1752) Ratios
Nang Kuang Pharmaceutical Co., Ltd. Ratios
TW:1752's free cash flow for Q2 2026 was NT$49.78M. For the 2026 fiscal year, TW:1752's free cash flow was decreased by NT$-37.30M and operating cash flow was NT$87.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.40 | 1.27 | 1.20 | 1.58 | 1.39 |
| Quick Ratio | 0.78 | 0.72 | 0.60 | 0.83 | 0.79 |
| Cash Ratio | 0.32 | 0.26 | 0.30 | 0.39 | 0.39 |
| Solvency Ratio | 0.32 | 0.31 | 0.26 | 0.45 | 0.32 |
| Operating Cash Flow Ratio | 0.44 | 0.41 | 0.27 | 0.35 | 0.52 |
| Short-Term Operating Cash Flow Coverage | 0.99 | 0.99 | 0.58 | 0.97 | 1.13 |
| Net Current Asset Value | NT$ 158.91M | NT$ 65.07M | NT$ 58.61M | NT$ 466.81M | NT$ 302.71M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.17 | 0.16 | 0.11 | 0.16 |
| Debt-to-Equity Ratio | 0.26 | 0.26 | 0.25 | 0.17 | 0.24 |
| Debt-to-Capital Ratio | 0.21 | 0.21 | 0.20 | 0.15 | 0.19 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.06 | 0.05 | 0.01 | 0.02 |
| Financial Leverage Ratio | 1.54 | 1.57 | 1.62 | 1.49 | 1.53 |
| Debt Service Coverage Ratio | 0.90 | 0.91 | 0.65 | 1.38 | 0.76 |
| Interest Coverage Ratio | 34.41 | 55.62 | 36.19 | 86.33 | 66.15 |
| Debt to Market Cap | 0.17 | 0.15 | 0.13 | 0.06 | 0.13 |
| Interest Debt Per Share | 6.59 | 6.38 | 6.06 | 4.10 | 5.32 |
| Net Debt to EBITDA | 0.65 | 0.69 | 0.56 | 0.01 | 0.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 35.56% | 33.99% | 35.14% | 35.81% | 33.40% |
| EBIT Margin | 13.67% | 14.03% | 10.27% | 21.41% | 13.39% |
| EBITDA Margin | 22.14% | 22.35% | 18.73% | 30.49% | 23.48% |
| Operating Profit Margin | 13.67% | 13.98% | 12.09% | 21.52% | 13.13% |
| Pretax Profit Margin | 13.47% | 13.78% | 9.94% | 21.16% | 13.19% |
| Net Profit Margin | 11.28% | 11.06% | 9.23% | 18.14% | 11.02% |
| Continuous Operations Profit Margin | 11.28% | 11.06% | 9.23% | 18.14% | 11.02% |
| Net Income Per EBT | 83.79% | 80.28% | 92.85% | 85.72% | 83.54% |
| EBT Per EBIT | 98.47% | 98.59% | 82.21% | 98.31% | 100.43% |
| Return on Assets (ROA) | 6.38% | 6.38% | 5.15% | 9.82% | 5.72% |
| Return on Equity (ROE) | 9.82% | 10.05% | 8.35% | 14.60% | 8.75% |
| Return on Capital Employed (ROCE) | 10.72% | 11.52% | 10.10% | 16.42% | 9.92% |
| Return on Invested Capital (ROIC) | 7.67% | 7.86% | 7.62% | 12.23% | 6.85% |
| Return on Tangible Assets | 6.39% | 6.39% | 5.15% | 9.83% | 5.73% |
| Earnings Yield | 6.49% | 5.86% | 3.68% | 5.45% | 4.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.93 | 5.20 | 5.74 | 5.02 | 5.08 |
| Payables Turnover | 6.59 | 6.91 | 8.38 | 4.91 | 5.30 |
| Inventory Turnover | 2.10 | 2.31 | 1.83 | 1.60 | 1.85 |
| Fixed Asset Turnover | 1.00 | 1.01 | 1.10 | 1.19 | 1.05 |
| Asset Turnover | 0.57 | 0.58 | 0.56 | 0.54 | 0.52 |
| Working Capital Turnover Ratio | 5.84 | 7.74 | 5.03 | 3.81 | 3.94 |
| Cash Conversion Cycle | 179.96 | 175.56 | 219.64 | 227.02 | 200.17 |
| Days of Sales Outstanding | 61.54 | 70.22 | 63.60 | 72.74 | 71.86 |
| Days of Inventory Outstanding | 173.78 | 158.17 | 199.59 | 228.70 | 197.15 |
| Days of Payables Outstanding | 55.35 | 52.83 | 43.55 | 74.41 | 68.84 |
| Operating Cycle | 235.31 | 228.39 | 263.19 | 301.44 | 269.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 4.60 | 4.62 | 3.39 | 3.66 | 5.51 |
| Free Cash Flow Per Share | 1.82 | -0.59 | 0.41 | 2.72 | 3.93 |
| Dividend Paid and CapEx Coverage Ratio | 1.28 | 0.74 | 0.68 | 1.47 | 1.79 |
| Capital Expenditure Coverage Ratio | 1.65 | 0.89 | 1.14 | 3.92 | 3.48 |
| Operating Cash Flow Coverage Ratio | 0.71 | 0.73 | 0.57 | 0.90 | 1.04 |
| Operating Cash Flow to Sales Ratio | 0.21 | 0.21 | 0.16 | 0.19 | 0.31 |
| Free Cash Flow Yield | 4.87% | -1.43% | 0.78% | 4.26% | 10.09% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 15.41 | 17.07 | 27.19 | 18.31 | 20.08 |
| Price-to-Sales (P/S) Ratio | 1.74 | 1.89 | 2.51 | 3.33 | 2.21 |
| Price-to-Book (P/B) Ratio | 1.51 | 1.72 | 2.27 | 2.68 | 1.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 20.54 | -69.86 | 128.75 | 23.46 | 9.91 |
| Price-to-Operating Cash Flow Ratio | 8.10 | 8.91 | 15.74 | 17.48 | 7.07 |
| Price-to-Earnings Growth (PEG) Ratio | 37.15 | 0.74 | -0.62 | 0.23 | 3.05 |
| Enterprise Value Multiple | 8.50 | 9.14 | 13.95 | 10.92 | 9.69 |
| Enterprise Value | 4.07B | 4.49B | 5.62B | 6.46B | 4.05B |
| EV to EBITDA | 8.50 | 9.14 | 13.95 | 10.92 | 9.69 |
| EV to Sales | 1.88 | 2.04 | 2.61 | 3.33 | 2.28 |
| EV to Free Cash Flow | 22.24 | -75.52 | 134.18 | 23.49 | 10.20 |
| EV to Operating Cash Flow | 8.77 | 9.63 | 16.40 | 17.50 | 7.28 |
| Tangible Book Value Per Share | 24.65 | 23.94 | 23.45 | 23.84 | 22.13 |
| Shareholders’ Equity Per Share | 24.64 | 23.98 | 23.50 | 23.87 | 22.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.16 | 0.20 | 0.07 | 0.14 | 0.16 |
| Revenue Per Share | 21.45 | 21.78 | 21.26 | 19.21 | 17.63 |
| Net Income Per Share | 2.42 | 2.41 | 1.96 | 3.49 | 1.94 |
| Tax Burden | 0.84 | 0.80 | 0.93 | 0.86 | 0.84 |
| Interest Burden | 0.98 | 0.98 | 0.97 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 |
| SG&A to Revenue | 0.13 | 0.12 | 0.12 | 0.12 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.59 | 1.92 | 1.60 | 0.90 | 2.37 |
Currency in TWD
